Fulltext

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

El Bairi K 1 , Haynes HR 2 , Blackley E 3 , Fineberg S 4 , Shear J 5 , Turner S 6 Show all authors , de Freitas JR 7 , Sur D 8 , Amendola LC 9 , Gharib M 10 , Kallala A 11 , Arun I 12 , Azmoudeh-Ardalan F 13 , Fujimoto L 14 , Sua LF 15 , Liu SW 16 , Lien HC 17 , Kirtani P 18 , Balancin M 19 , El Attar H 20 , Guleria P 21 , Yang W 22 , Shash E 23 , Chen IC 24 , Bautista V 25 , Do Prado Moura JF 26 , Rapoport BL 27 , Castaneda C 28 , Spengler E 29 , Acosta-Haab G 30 , Frahm I 31 , Sanchez J 32 , Castillo M 32 , Bouchmaa N 33 , Md Zin RR 34 , Shui R 35 , Onyuma T 36 , Yang W 35 , Husain Z 37 , Willard-Gallo K 38 , Coosemans A 39 , Perez EA 40 , Provenzano E 41 , Ericsson PG 42 , Richardet E 43 , Mehrotra R 44 , Sarancone S 45 , Ehinger A 46 , Rimm DL 47 , Bartlett JMS 48 , Viale G 49 , Denkert C 50 , Hida AI 51 , Sotiriou C 52 , Loibl S 53 , Hewitt SM 54 , Badve S 55 , Symmans WF 56 , Kim RS 57 , Pruneri G 58 , Goel S 3 , Francis PA 59 , Inurrigarro G 60 , Yamaguchi R 61 , Garcia-Rivello H 62 , Horlings H 63 , Afqir S 64 , Salgado R 3 , Adams S 65 , Kok M 66 , Dieci MV 67 , Michiels S 68 , Demaria S 69 , Loi S 3 , International Immuno-Oncology Biomarker Working Group

Affiliations 

  • 1 Department of Medical Oncology, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy, Mohammed Ist University, Oujda, Morocco. k.elbairi@ump.ac.ma
  • 2 Department of Cellular Pathology, Great Western Hospital, Swindon, UK
  • 3 Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia
  • 4 Department of Pathology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY, USA
  • 5 Chief Information Officer, WISS & Company, LLP and President J. Shear Consulting, LLC-Ardsley, Ardsley, NY, USA
  • 6 ICPV, Independent Cancer Patient Voice, London, UK
  • 7 Department of Pathology and Legal Medicine, Medical School of the Federal University of Bahia, Salvador, Brazil
  • 8 Department of Medical Oncology, University of Medicine "I. Hatieganu", Cluj Napoca, Romania
  • 9 Brazilian Society of Oncology, Salvador, Brazil
  • 10 Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  • 11 Hopital Charles Nicolle, Tunis, Tunisia
  • 12 Department of Histopathology, Tata Medical Center, Kolkata, India
  • 13 Department of Pathology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
  • 14 Pathology and Legal Medicine, Amazon Federal University, Belém, Brazil
  • 15 Department of Pathology and Laboratory Medicine, Fundacion Valle del Lili, and Faculty of Health Sciences, Universidad ICESI, Cali, Colombia
  • 16 Sichuan Cancer Hospital, Chengdu, China
  • 17 Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan
  • 18 Department of Histopathology, Manipal Hospitals Dwarka, New Delhi, India
  • 19 Department of Pathology, Faculty of Medicine, University of São Paulo, São Paulo, Brazil
  • 20 Apc labs - Annasr Pathology Center, El Jadida, Morocco
  • 21 Army Hospital Research and Referral, Delhi Cantt, New Delhi, India
  • 22 Aginome Scientific Pte Ltd, Xiamen, China
  • 23 Breast Cancer Comprehensive Center, National Cancer Institute, Cairo University, Cairo, Egypt
  • 24 Department of Oncology, National Taiwan University Cancer Center, Taipei, Taiwan
  • 25 Department of Pathology, Breast Cancer Center FUCAM, Mexico City, Mexico
  • 26 Centro de Pesquisas Clinicas do IMIP, Recife, Brazil
  • 27 The Medical Oncology Centre of Rosebank, Johannesburg, South Africa
  • 28 Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Lima, 15038, Peru
  • 29 Departmento de Patologia, Hospital Universitario Austral, Pilar, Argentina
  • 30 Department of Pathology, Hospital de Oncología Maria Curie, Buenos Aires, Argentina
  • 31 Department of Pathology, Sanatorio Mater Dei, Buenos Aires, Argentina
  • 32 Department of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima, 15038, Peru
  • 33 Institute of Biological Sciences, Mohammed VI Polytechnic University (UM6P), 43 150, Ben-Guerir, Morocco
  • 34 Department of Pathology, Faculty of Medicine, UKM Medical Centre, Kuala Lumpur, Malaysia
  • 35 Department of Pathology, Fudan University Cancer Center, Shanghai, China
  • 36 Kenyatta National Hospital, Nairobi, Kenya
  • 37 Praava Health, Dhaka, Bangladesh
  • 38 Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
  • 39 Laboratory of Tumour Immunology and Immunotherapy, Department of Oncology, KU Leuven, Leuven, Belgium
  • 40 Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, USA
  • 41 Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
  • 42 Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA
  • 43 Clinical Oncology Unit, Instituto Oncológico Córdoba, Córdoba, Argentina
  • 44 India Cancer Research Consortium-ICMR, Department of Health Research, New Delhi, India
  • 45 Department of Pathology, Laboratorio QUANTUM, Rosario, Argentina
  • 46 Department of Clinical Genetics and Pathology, Skåne University Hospital, Lund University, Lund, Sweden
  • 47 Department of Pathology, Yale School of Medicine, New Haven, CT, USA
  • 48 Diagnostic Development, Ontario Institute for Cancer Research, Toronto, Canada
  • 49 Department of Pathology, Istituto Europeo di Oncologia IRCCS, and University of Milan, Milan, Italy
  • 50 Institute of Pathology, Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg and Philipps-Universität Marburg, Marburg, Germany
  • 51 Department of Pathology, Matsuyama Shimin Hospital, Matsuyama, Japan
  • 52 Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
  • 53 German Breast Group, Neu-Isenburg, Germany
  • 54 Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, MD, USA
  • 55 Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, USA
  • 56 Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
  • 57 National Surgical Adjuvant Breast and Bowel Project (NSABP)/NRG Oncology, Pittsburgh, PA, USA
  • 58 Department of Pathology, RCCS Fondazione Istituto Nazionale Tumori and University of Milan, School of Medicine, Milan, Italy
  • 59 Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia
  • 60 Department of pathology Sanatorio Mater Dei, Buenos Aires, Argentina
  • 61 Department of Pathology and Laboratory Medicine, Kurume University Medical Center, Kurume, Fukuoka, Japan
  • 62 Servicio de Anatomía Patológica, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
  • 63 Division of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  • 64 Department of Medical Oncology, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy, Mohammed Ist University, Oujda, Morocco
  • 65 Perlmutter Cancer Center, New York University Medical School, New York, NY, USA
  • 66 Divisions of Medical Oncology, Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  • 67 Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy
  • 68 Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Oncostat U1018, Inserm, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France
  • 69 Department of Radiation Oncology, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
NPJ Breast Cancer, 2021 Dec 01;7(1):150.
PMID: 34853355 DOI: 10.1038/s41523-021-00346-1

Abstract

The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications